Identification of transition from primary Raynaud's phenomenon to secondary Raynaud's phenomenon by nailfold videocapillaroscopy: Comment on the article by Hirschl et al

2007 ◽  
Vol 56 (6) ◽  
pp. 2102-2103 ◽  
Author(s):  
Maurizio Cutolo ◽  
Carmen Pizzorni ◽  
Alberto Sulli
2016 ◽  
Vol 36 (7) ◽  
pp. 1637-1642 ◽  
Author(s):  
Carmen Pizzorni ◽  
Alberto Sulli ◽  
Vanessa Smith ◽  
Barbara Ruaro ◽  
Amelia Chiara Trombetta ◽  
...  

2010 ◽  
Vol 37 (4) ◽  
pp. 783-786 ◽  
Author(s):  
BATSI CHIKURA ◽  
TONIA MOORE ◽  
JOANNE MANNING ◽  
ANDY VAIL ◽  
ARIANE L. HERRICK

Objective.To conduct a retrospective study to assess whether the degree of thumb involvement differs between primary Raynaud’s phenomenon (PRP) and secondary Raynaud’s phenomenon (SRP).Methods.Thermography images from all patients attending Salford Royal Hospital and referred for thermography for assessment of RP between 2004 and 2006 were retrospectively reviewed. A distal dorsal difference (DDD) of −1°C or less between the fingertips and dorsum of the hand (fingers cooler) at 23°C was considered clinically relevant. The worse score (the lower score, i.e., the more negative value) from each pair of digits was considered for analysis.Results.One hundred seventy patients fulfilled the study criteria. DDD at 23°C for the thumbs were significantly higher (digital tips warmer) compared with other digits (p < 0.001) in both PRP and SRP. All digits were significantly warmer in PRP compared to SRP with the exception of the thumbs. The proportion of patients with clinically relevant involvement of thumbs was significantly higher in SRP compared to PRP (p = 0.003) and this difference was more pronounced in the thumbs compared with other digits.Conclusion.Although the median temperature gradient along the thumb was not significantly different between SRP and PRP, the thumb is more likely to be involved in SRP than in PRP. Thumb involvement is one of a number of clinical indicators that should alert the clinician to the possibility of an underlying connective tissue disease/disorder.


2017 ◽  
Vol 7 (1) ◽  
pp. 90-98
Author(s):  
A. Kuryliszyn-Moskal ◽  
J. Kita ◽  
A. Hryniewicz

Purpose: The aim of the study was the assessment of the influence of MLS laser therapy on morphological changes in nailfold videocapillaroscopy (NVC), clinical features, and the serum NO level in patients with primary and secondary Raynaud’s phenomenon (RP). Materials and methods: The analysis was performed on a group of 78 patients with RP and 30 healthy volunteers, who underwent NVC examination. NO concentration was assayed using the Griess method in blood serum before and after 3-weeks of laser biostimulation. MLS wasperformed with a Laser-M6 ASA Company device,for 3 weeks with weekend breaks, using thefollowing parameters: a frequency of 1500 Hz, adose of 25 J/cm2, and a time of 2.5 minutes on onehand. Results: After 3 weeks of MLS laser therapy, thebeneficial clinical effects manifested by a decrease of duration and number of RP attacks and degree of pain score on the visual analogue scale (VAS) in patients with primary and secondary RP. Clinical improvement after MLS laser therapy was reflected in the assessment of microcirculation disorders in NVC examination. Moreover, the tendency of normalization of NO concentration in the serum of patients with primary and secondary RP may suggest a favorable effect of laser biostimulation on the regulation of processes taking part in microcirculation disorders. Conclusions: The results showed that NVC is a useful diagnostic tool in the evaluation of dynamic microvascular involvement in RP patients. MLS laser therapy has a beneficial effect in patients with primary and secondary Raynaud’s phenomenon


2016 ◽  
Vol 2016 ◽  
pp. 1-4
Author(s):  
Mohammed Shabrawishi ◽  
Abdurahman Albeity ◽  
Hani Almoallim

Raynaud’s phenomenon refers to reversible spasms of the peripheral arterioles that can be primary Raynaud’s phenomenon (PRP) or secondary Raynaud’s phenomenon (SRP) to underlying connective tissue disease, both of which are characterized by a triphasic color response triggered by cold exposure or stress. PRP is typically a benign disease, whereas SRP may progress into digital ulcers and/or gangrene. Here, we report a case of a 55-year-old female diagnosed with PRP 7 years ago. Treatment with first-line agents, including calcium channel blocker, aspirin, and phosphodiesterase inhibitor, did not control her symptoms, which progressed to digital ulceration and gangrene. There were no symptoms of underlying autoimmune disease or malignancy, and autoimmune, serology, and immunology test results were normal; a biopsy of her left little finger was negative for vasculitis. Development to critical digital ischemia necessitated treatment with intravenous iloprost and heparin infusion followed by angioplasty, which led to a partial improvement. Due to persistent symptoms, rituximab therapy was initiated and two cycles induced a complete resolution of symptoms.


2012 ◽  
Vol 10 (3) ◽  
pp. 535-537 ◽  
Author(s):  
A. Riccio ◽  
M.G. Sangiolo ◽  
G. Tarantino

The heritability of primary Raynaud's phenomenon has been reported in previous works. In this paper we describe the simultaneous onset of Raynaud's phenomenon, rapidly evolved in acrocyanosis and diagnosed as secondary Raynaud's phenomenon, observed in monozygotic twins. This case supports the role of genetic factors in the pathogenesis of such disorder. Moreover, the singular synchronism of its appearance is discussed.


1994 ◽  
Vol 86 (3) ◽  
pp. 269-273 ◽  
Author(s):  
Jay D. Coffman ◽  
Richard A. Cohen

1. The involvement of plasma 5-hydroxytryptamine in normal subjects during sympathetic stimulation and in patients with Raynaud's phenomenon was studied. 2. Arterial and venous plasma levels of 5-hydroxytryptamine were measured in normal subjects in a warm room, during reflex sympathetic stimulation by body cooling and during intra-arterial infusions of tyramine. Normal subjects (n = 19) had significantly higher levels of 5-hydroxytryptamine in venous plasma [mean 1.42 (SEM 0.23) ng/ml] than in arterial plasma [0.67 (0.12) ng/ml; P < 0.01]. Body cooling (n = 10) or tyramine infusion (n = 8) did not increase venous levels of 5-hydroxytryptamine despite significant decreases in blood flow and increases in vascular resistance. 3. Venous plasma levels of 5-hydroxytryptamine were also determined in patients with primary Raynaud's phenomenon (n = 12) or secondary Raynaud's phenomenon due to scleroderma (n = 11). Patients with primary or secondary Raynaud's phenomenon did not have significantly higher venous plasma levels of 5-hydroxytryptamine than normal subjects, even during vasospastic attacks (n = 3). 4. It is concluded that either 5-hydroxytryptamine is not involved in sympathetic nerve vasoconstriction or in Raynaud's phenomenon, or 5-hydroxytryptamine released in the microcirculation is largely taken up or metabolized by endothelial cells or platelets.


Sign in / Sign up

Export Citation Format

Share Document